Evidence map›Paper›PMID 41377059›Full record

ArticleOphthalmology science2026

Genetic Background Predicts Uveal Melanoma Patients' Outcomes.

Thibault Verrier, Anaïs Le Ven, Alexandre Houy, Erwin Brosens, Emine Kilic, Wishal D Ramdas, Tolga Bicer, Agathe Garcia, Anne-Charlotte Lefranc, Sandra Vanhuele and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Thibault VerrierINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Anaïs Le VenINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Alexandre HouyINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Erwin BrosensClinical Genetics Department, Erasmus MC, Rotterdam, The Netherlands.
Emine KilicErasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.
Wishal D RamdasDepartment of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.
Tolga BicerErasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.
Agathe GarciaINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Anne-Charlotte LefrancINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Sandra VanhueleINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Amanda F KahnINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Gaelle PierronUniversité Paris Sciences & Lettres, Paris, France.
Alexandre MatetDépartement d'Oncologie Oculaire, Institut Curie, Paris, France.
Nathalie CassouxDépartement d'Oncologie Oculaire, Institut Curie, Paris, France.
Chrystelle ColasINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Manuel RodriguesINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.
Josselin NoirelLaboratoire GBCM (EA7528), Conservatoire National des Arts et Métiers (CNAM), Paris, France.
Marc-Henri SternINSERM U1339 CNRS UMR3666, DNA Repair and Uveal Melanoma (D.R.U.M.), Institut Curie, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Single nucleotide polymorphisms (SNPs) in Design: Cohort study from Institut Curie, Paris (France) and Erasmus University Medical Center, Rotterdam (The Netherlands). Participants: Patients diagnosed with UM at Institut Curie ( Methods: Impact of Main Outcome Measures: We analyzed risk SNPs in the series of patients with UM in relation to tumor and patient characteristics, including eye color, tumor subtype and diameter, and patient outcomes. Results: Conclusions: Our study demonstrates that inherited polymorphisms in Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Genetic backgroundPredictive modelPrognosticationUveal melanoma

Identifiers

PMID41377059
PMCPMC12686906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.